"The significance of this study is that we found the chromosomal regions involved and can now zero in on the precise genes," said Diane Mathis, Ph.D., the study's principal investigator along with Christophe Benoist, M.D., Ph.D. They head the Section on Immunology and Immunogenetics at Joslin, and hold joint William T. Young Chairs in Diabetes Research. They are also Professors of Medicine at Harvard Medical School. The work was spearheaded by a group of Joslin fellows, hailing from across the globe: Silvia Zucchelli, Ph.D., who has now returned to Italy; Phil Holler, Ph.D., from the U.S.; and Tetsuya Yamagata, M.D., Ph.D, from Japan.
The genetic defect keeps the body from properly dealing with "errant" immune cells that it normally eliminates by a process called immunological tolerance. These immune cells then attack the insulin-producing beta cells in the pancreas, mistaking them as foreign invaders.
"It's critical for the immune system to recognize and tolerate tissues that belong in the body, which immunologists call 'tolerance,'" said Dr. Zucchelli. "Previous studies have shown that when the T-cells don't learn this tolerance, they can infiltrate the pancreas and attack the insulin-producing beta cells." This first step in the onset of type 1 diabetes is called insulitis. Later in life, within weeks or even years, full-blown type 1 diabetes emerges.
An estimated 1 million people in the United States have type 1 diabetes. Their pancreatic beta cells can no longer make insulin. Without this crucial hormone, their body cannot convert food into energy. To sustain life, they must get insulin through injections. The disorder can emerge in childhood, adolescence and even appear in adulthood, but the genetic stage is set beforehand.
T-cells play a key role. They are part of the highly complex array of immune cells that normally work together to fight invaders such as bacteria or viruses, adapting specifically to each new invader. Formed in the thymus gland, T-cells begin as "precursor" cells and mature -- during this time, receptor sites on their outer membrane are shaped to dock with each invader and destroy it.
"As T-cells form, it is not uncommon for a few to randomly develop with the potential ability to attack the body's own cells," said Dr. Holler. "That's when a safeguard mechanism normally kicks in to eliminate these errant T-cells. Our team found the genetic regions that govern this safeguard."
What if the safeguard mechanism is defective? Left unchecked, the self-destructive T-cells can roam throughout the body and wreak havoc. This is the process behind many autoimmune, or "self-immune," diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis and others.
To understand what happens in type 1 diabetes, the researchers combined a unique set of cutting-edge technologies, using cultures of thymus cells from transgenic mice, together with DNA chips and "genome scans." They compared non-obese diabetic (NOD) mice, which researchers elsewhere had shown to have the tolerance defect, with diabetes-resistant controls. They looked for regions where the data from the DNA chips and the genome scan converged. Overlap would indicate the regions and genes that affect tolerance.
In the mice with diabetes, two findings emerged -- a distinct decrease of activity in regions that governed the elimination of errant T-cells, and an increase of activity promoting their survival. The safeguard system was broken. The T-cells were alive and able to leave the thymus and attack beta cells.
Now that the chromosomal regions are known, the researchers are seeking the precise genes involved. "Once these genes are identified, we will be better able to define the biologic pathways that lead to type 1 diabetes," said Dr. Yamagata. "We then can work on designing ways to subdue or stop this process."
This study was supported by the Juvenile Diabetes Research Foundation (JDRF), in the context of the JDRF Center on Immunological Tolerance in Type-1 Diabetes at Harvard Medical School.
About Joslin Diabetes Center
Joslin Diabetes Center, dedicated to conquering diabetes in all of its forms, is the global leader in diabetes research, care and education. Founded in 1898, Joslin is an independent nonprofit institution affiliated with Harvard Medical School. Joslin research is a team of more than 300 people at the forefront of discovery aimed at preventing and curing diabetes. Joslin Clinic, affiliated with Beth Israel Deaconess Medical Center in Boston, the nationwide network of Joslin Affiliated Programs, and the hundreds of Joslin educational programs offered each year for clinicians, researchers and patients, enable Joslin to develop, implement and share innovations that immeasurably improve the lives of people with diabetes. As a nonprofit, Joslin benefits from the generosity of donors in advancing its mission. For more information on Joslin, call 1-800-JOSLIN-1 or visit www.joslin.org.